Tag: Migraine
FDA Approves Symbravo for Acute Treatment of Migraine in Adults
Symbravo can rapidly eliminate migraine pain within two hours, with efficacy sustained through 24 and 48 hours, across migraine pain severity
Propranolol May Reduce Overall Stroke Risk in Women With Migraine
Protective effect more pronounced for ischemic stroke and in women with migraine without aura
Atogepant Superior for Efficacy, Functional Measures in Migraine
Reductions in weekly migraine days seen at weeks 1 to 4 and in monthly migraine days in first four weeks
Older Adults With Migraine Experienced Higher Depression Risk During Pandemic
Findings particularly pronounced for those experiencing pandemic-related stressors
FDA Approves Nerivio for Migraine Treatment in Children Aged 8 Years and Older
Device becomes the first and only remote electrical neuromodulation wearable for migraine treatment for children 8 years and older
Clinical Practice Guideline Updated for Migraine, Tension-Type Headache
Guidelines include 52 recommendations on evaluation, pharmacotherapy, invasive interventions, and nonpharmacologic interventions
Study Addresses Differentiating Meniere Disease, Vestibular Migraine
Dissociation between pathological caloric testing, normal video head impulse test can differentiate Meniere disease from vestibular migraine
Review Compares Drug Interventions for Acute Migraine Treatment
Eletriptan most effective for pain freedom at two hours in head-to-head comparisons, followed by rizatriptan, sumatriptan, and zolmitriptan
Erenumab Effective for Nonopioid Medication Overuse Headache in Chronic Migraine
Safety profile similar to other trials, with six in 10 sustaining medication overuse headache remission over six months
Monoclonal Antibody Tops Placebo for Reducing Migraine Frequency
Humanized mAb directed against pituitary adenylate cyclase-activating polypeptide ligand reduces migraines over four weeks